Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.



Ascenion’s Annual Review 2019: New impetus for start-ups

Supporting start-ups has always been a particular focus of our activities. In 2019, we have seen significant successes and opposing trends in this area. Here our summary of highlights, figures and key developments in the start-up field and beyond.


5-point plan to boost technology transfer and stimulate economic growth

The TransferAllianz proposes 5 measures to leverage the innovation potential of academic research and drive sustainable economic recovery following the corona crisis.

Aignostics Raises €5 Million Seed Round to Advance AI-Powered Pathology

BERLIN, 28 August 2020 – Aignostics, a spin-off from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) pioneering…

[Translate to English:]

T-knife Completes €66 Million Series A Financing to Develop Next Generation T-Cell Therapies

  • T-knife’s proprietary humanized mouse platform (HuTCR) T-cell Receptors expected to provide superior affinity/specificity properties
  • Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF

Ascenion’s portfolio company HepaRegeniX reports impressive preclinical data on its liver disease candidate

HepaRegeniX has demonstrated proof-of-efficacy in acute liver disease in preclinical studies performed in collaboration with the University Hospital of Tübingen (Germany) and the Mayo Clinic (Rochester, MN, USA).

[Translate to English:]

Ascenion strengthens legal team

Ascenion welcomes a new colleague to the Munich office: Cristina Romano joined the company as Legal Counsel in July 2020, bringing over 15 years’ professional experience to the team.

Webinars on gene- and cell-therapy projects presented by Ascenion & Oxford University Innovation

Join us on 24 June and on 1 July 2020 for our webinars, presenting the top licensable projects in the field of gene and cell therapy from Ascenion’s and Oxford University Innovation’s (OUI) portfolios.

[Translate to English:]

Welcome to the team!

Dr Julia Niemann joined Ascenion’s team in Hannover in April 2020 as Technology Scout. Her main focus will be on projects at the Hannover Medical…

[Translate to English:]

Charité spin-off dentalXrai offers AI platform for better dental decisions

Newly founded dentalXrai provides a unique, AI-based platform to improve and speed up the analysis of dental X-ray images. Ascenion, technology transfer partner of the Charité – Universitätsmedizin Berlin, holds equity in the start-up.

[Translate to English:]

Diffratec Optics OG - a MUI spin-off - licensed innovative diffractive technologies

Diffratec, a spin-off from the Medical University of Innsbruck (MUI), commercializes breakthrough diffractive elements. These elements, in particular Moiré lenses, are extremely compact and tunable with high speed and precision.

Professional translation from the perspective of active investors and selected Tech Transfer Officers

In a round table discussion, the translation of scientific ideas into valid projects and commercial assets was highlighted by five companies.


[Translate to English:]

MDC collaboration partner Formula Pharmaceuticals completes merger with CoImmune

Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.

Start-Up PROVIREX: Innovative approach to curing HIV infection

Ascenion and Innovationsstarter Fonds Hamburg acquire equity in Hamburg start-up – innovative therapeutic approach enters clinical testing

[Translate to English:]

Coronavirus: Current information

Dear clients, partners and technology transfer colleagues,

In these unprecedented and worrying times dominated by the coronavirus pandemic, we remain…

[Translate to English:]

New data support therapeutic approach of Ascenions portfolio company Cardior

Cardior Pharmaceuticals GmbH has published results of preclinical in vivo studies in Nature Communications showing that its lead compound, CDR132L, can significantly improve the functioning of pathologically altered hearts.


[Translate to English:]

BIO-Europe Digital

Global Partnerships that drive Life Science dealmaking

Cancelled - 10. Transferwerkstatt

Bolle Festsäle

Berlin, Germany

BioFIT 2020 Digital

[Translate to English:]

AUTM Annual Meeting 2021

Washington State Convention Center
Seattle, Washington, USA

[Translate to English:]

BioVaria 2021

Sofitel Munich Bayerpost
Munich, Germany

[Translate to English:]

ASTP Annual Conference 2021

Altis Grand Hotel

Lisbon, Portugal